MediciNova Announces MN-166 (ibudilast) Poster Presentation at the 32nd International Symposium on ALS/MND
10. Dezember 2021 06:30 ET
|
MediciNova, Inc.
LA JOLLA, Calif., Dec. 10, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
MediciNova Announces New Data regarding MN-166 (ibudilast) in Glioblastoma Presented at the 26th Annual Meeting of the Society for Neuro-Oncology
22. November 2021 06:30 ET
|
MediciNova, Inc.
LA JOLLA, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
MediciNova Announces MN-001 (tipelukast) Data regarding Lipid Metabolism in NASH/NAFLD to be Presented at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases
11. November 2021 18:00 ET
|
MediciNova, Inc.
LA JOLLA, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
MediciNova Announces New Data regarding MN-166 (ibudilast) in Uveal Melanoma Presented at the CURE OM Global Science Meeting
10. November 2021 18:00 ET
|
MediciNova, Inc.
LA JOLLA, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
MediciNova Announces New Data regarding MN-166 (ibudilast) in Glioblastoma to be Presented at the Annual Meeting of the Society for Neuro-Oncology
03. November 2021 19:30 ET
|
MediciNova, Inc.
LA JOLLA, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
MediciNova Announces Abstract regarding the Mechanism by which MN-001 (tipelukast) Alters Triglyceride Metabolism Accepted for Presentation at the 19th International Symposium on Atherosclerosis (ISA2021)
21. Oktober 2021 06:30 ET
|
MediciNova, Inc.
LA JOLLA, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
MediciNova to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
02. September 2021 23:00 ET
|
MediciNova, Inc.
LA JOLLA, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
MediciNova Announces MN-001 (tipelukast) Abstract regarding Lipid Metabolism in NASH/NAFLD Accepted for Presentation at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases
01. September 2021 06:30 ET
|
MediciNova, Inc.
LA JOLLA, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 32nd International Symposium on ALS/MND
30. August 2021 06:30 ET
|
MediciNova, Inc.
LA JOLLA, Calif., Aug. 30, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
MediciNova Reports Second Quarter 2021 Financial Results and Business Update
12. August 2021 19:00 ET
|
MediciNova, Inc.
Initiated preclinical animal studies for MN-166 as a treatment for chlorine gas-induced induced lung disease under partnership with BARDA Positive Phase 2 results in alcohol use disorder published in...